Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc.

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, with a price targ...

Recursion Pharmaceuticals (RXRX) Gets a Hold from Bank of America Securities

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals yesterday. The company’s shares closed yesterday at $3.17. Smi...

TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmace...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RXRX	$3.16	-4.53%	10.46M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RXRX	$3.16	-4.5%	10.46M
3
4
5
6

RXRX

Get Recursion Pharmaceuticals, Inc. Data in Excel

Get Recursion Pharmaceuticals, Inc. Data in Excel